




RealRate

PHARMACEUTICAL 2021

Flexion Therapeutics Inc
Rank 238 of 409



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2021

Flexion Therapeutics Inc Rank 238 of 409

The relative strengths and weaknesses of Flexion Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Flexion Therapeutics Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 74% points. The greatest weakness of Flexion Therapeutics Inc is the variable Assets, Current, reducing the Economic Capital Ratio by 61% points.

The company's Economic Capital Ratio, given in the ranking table, is -184%, being 170% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	225,811
Cost of Goods Sold	19,249
Intangible Assets	0
Liabilities, Current	55,268
Liabilities, Non-Current	50,532
Other Assets	6,577
Other Compr. Net Income	-73
Other Expenses	495
Other Liabilities	162,786
Other Net Income	-20,192
Property and Equipment	19,538
Research and Development	54,326
Revenues	85,552
Selling, General and Administrative Expense	104,996

Output Variable	Value in 1000 USD
Assets	251,926
Liabilities	268,586
Expenses	179,066
Stockholders Equity	-16,660
Net Income	-113,706
Comprehensive Net Income	-113,742
Economic Capital Ratio	-184%

